Archived

The 5 FDA 483 Observations That Keep Coming Back (And What They Actually Mean)

FDA has cited laboratory controls as its most frequent drug manufacturing observation for fourteen consecutive years running. The problem isn’t that pharma companies don’t know the regulation. The problem is they keep misdiagnosing what the observation actually means. I’m Khaled Aamer, founder of XGene LLC, and I’ve written 483 responses across six sterile manufacturing remediations. […]

The 5 FDA 483 Observations That Keep Coming Back (And What They Actually Mean) Read More »

Inspection Readiness: The 90-Day CMC Preparation Framework

Welcome to the XGene Regulatory Intelligence podcast. I’m Khaled Aamer, founder and principal consultant at XGene LLC. This episode walks through something that consistently separates sites that pass FDA inspections cleanly from sites that keep collecting preventable 483 observations: how they spend the 90 days before the investigator arrives. The companies that perform best in

Inspection Readiness: The 90-Day CMC Preparation Framework Read More »